SKN | Goldman Sachs Adds UnitedHealth to Conviction List, Signals Managed Care Turning Point

Key Takeaways:

• Goldman Sachs adds UnitedHealth Group to its Conviction List with a $435 target.
• Improving medical cost trends suggest Medicare Advantage pressures may be easing.
• Strong earnings and capital returns support a potential recovery narrative.

Goldman’s High-Conviction Signal

Goldman Sachs placing UnitedHealth Group on its Conviction List is a notable signal. This list represents the firm’s highest-confidence investment ideas, indicating a strong belief in upside potential despite recent volatility.

The move comes after a sharp rebound in the stock, suggesting Goldman sees further room for gains beyond the recent rally.

Medicare Advantage Cycle Nearing Bottom

Goldman’s core thesis centers on the Medicare Advantage (MA) business, which accounts for roughly 40% of UnitedHealth’s operations.

The firm believes the underwriting cycle—pressured by elevated medical costs in 2025—is now nearing a bottom. If correct, improving pricing discipline and cost control could drive earnings recovery over the coming quarters.

Improving Cost Trends Support the Thesis

Recent results support this view. UnitedHealth’s medical care ratio showed meaningful improvement, signaling better cost management and stabilizing utilization trends.

Stronger-than-expected earnings also reinforced confidence, suggesting the worst of margin pressure may already be behind the company.

Reinforced by Broader Wall Street Support

Bank of America also maintains a Buy rating with a similar $435 target, adding weight to the bullish outlook.

When multiple major institutions align on valuation and outlook, it often strengthens investor confidence and can support sustained momentum in the stock.

Strong Business Scale and Diversification

UnitedHealth Group continues to benefit from its dual-platform model—UnitedHealthcare and Optum—serving tens of millions of members while expanding into pharmacy, care delivery, and data-driven services.

Ongoing investments in AI and healthcare technology further position the company for long-term operational efficiency and growth.

Risks Still in Focus

Despite the improving outlook, risks remain. Membership declines in certain segments and ongoing regulatory scrutiny, including legal uncertainties tied to Medicare participation, could weigh on sentiment.

Additionally, after a strong rally, valuation may limit near-term upside if execution does not continue to improve.

Market Interpretation

Goldman’s Conviction List addition is generally viewed as a strong bullish signal. It reflects confidence not only in valuation but also in a turning point in underlying business fundamentals.

However, the market may balance this optimism with caution given recent price gains and lingering regulatory risks.

Outlook

Looking ahead, the trajectory of UnitedHealth Group will depend on sustained improvement in medical cost ratios, stable membership trends, and regulatory clarity.

Goldman Sachs’s call suggests the managed care sector may be entering a recovery phase—but confirmation will depend on continued execution in upcoming quarters.

For confidential insights on healthcare sector trends, institutional positioning, and high-conviction stock opportunities, connect with the SKN team for professional engagement.